1st Aug 2025 12:52
Oxford Biomedica PLC - Oxford, England-based gene and cell therapy developer - Says it has a new loan facility with Oaktree Capital Management LP worth up to USD125 million over four years. Expects USD60 million upfront funding to be available when the deal closes. Plans to use this to repay an existing USD50 million loan from Oaktree. Notes that the loan includes option to draw down further USD25 million and additional USD40 million, subject to revenue targets. Says this increases flexibility to grow global contract development and manufacturing operations. Notes also that the loan will not amortise, with the full aggregate principal and outstanding amount due in 2029.
Chief Financial Officer Lucina Crabtree comments: "Oaktree's continued support reflects their long-standing confidence in OXB's leading position in the CDMO viral vector market and enables us to remain focused on enhancing our capabilities."
Current stock price: 439.34 pence on Friday afternoon in London
12-month change: up 18%
By Holly Munks, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Oxford Biomedica